A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

MediciNova, Inc. MNOV

Weak (early) broader-coverage candidate · MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficie

On FrontierLab's discovery record since 2026-09-17 (2 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-18), not the curated Frontier signal.

⚡ Surfaced on a price move — momentum is where to look, not a buy signal. The move that surfaced this name does not make it a good entry.

⚠ Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.

Key quality signals

Revenue growth (YoY)	—
Gross margin	—
Gross profits / assets	0.01
Rule of 40	-703.5
Net margin	-1287.4%
Cash runway (months)	0.2
PEG	—
Price / sales	184.5

Quality checklist

✗ Capital efficiency
✓ Share dilution — 0.4%

Fundamentals — snapshot as of 2026-09-18

Stage	Early
Share issuance (YoY)	0.4% · flat share count
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-0.22
Burn multiple	—
Gross-margin trend (pts)	—
Cash / assets	0.63
Net debt / EBITDA	—
Statements as of	Q2 FY2026 · filed 2026-08-13

Momentum context — a snapshot from 2026-09-18, not current

Price at surface	$3.45 (as of 2026-09-18)
52-week range	$1.17 – $3.8999
% off 52-wk high	-11.5%
RSI (14)	94
Relative volume	14.6×

Risk flags

Burning cash — operating margin is negative.Cash runway ~0 months at current burn — a dilutive raise looks imminent.Parabolic one-day spike (+37%) in the last month — extreme single-day moves tend to mean-revert.Volume 14.6× normal alongside the move — attention-crowded names tend to reverse over the following weeks.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-09-18 (end-of-day). How grades are computed →